WeightWatchers rebuilds around GLP-1 users with prescribing arm and no-prescription track
WeightWatchers is pairing brand-only GLP-1 prescribing with its behavior-change tools, so patients comparing programs are weighing a recurring membership fee on top of the same drug prices offered elsewhere.
WeightWatchers rebuilt its platform around GLP-1 users, adding prescribing through a clinical program called Med+ and a no-prescription track for people already taking one of the drugs from another prescriber, the company said in a December 16, 2025 release [1]. The relaunch came with new company figures on weight loss and side effects among members taking the medications [1].
What the rebuilt program includes
Med+ is membership-based. Licensed clinicians evaluate members and can prescribe GLP-1 medications when appropriate, and members have to qualify based on BMI and health history [1]. The medication menu is brand-only: Wegovy injection and pill, Zepbound, Saxenda, the Foundayo pill, metformin and naltrexone/bupropion, dispensed through mail-order partner Carepoint in Schaumburg, Illinois [1]. No compounded GLP-1 appears on any WW page; third-party reviewers date the exit from compounded semaglutide to May 2025, after the FDA declared the tirzepatide shortage resolved on December 19, 2024 and the semaglutide shortage resolved on February 21, 2025 [1].
The second piece is GLP-1 Success, a no-prescription track advertised at $20 a month as a limited offer for people already on a GLP-1 from another prescriber [1]. WW's general pitch is that medication comes wrapped in its long-running behavioral system: points, food tracking, coaching and community [1].
The company's own results
WW reported an average 21% body-weight loss at 12 months among Med+ members taking a GLP-1, based on company data from about 3,250 patients that has not been peer reviewed, and said more than 70% of surveyed Med+ members feel the program helps minimize side effects [1]. The same release cites a WW-commissioned survey in which 90% of GLP-1 users said they want community support [1].
The 21% figure sits where the drug itself sits rather than above it. The Zepbound label reports 20.9% mean weight loss at 72 weeks on the 15 mg dose and 15.0% on the 5 mg dose in the SURMOUNT-1 trial [1]. Because WW's number has no comparison group, it does not show that coaching adds weight loss beyond the medication [1].
Cost and coverage
As read from weightwatchers.com on September 5, 2026, Med+ membership is $25 a month for the first two months of a 12-month plan and $74 a month after that, with medication billed separately [1]. Cash-pay Zepbound through LillyDirect runs $299, $399 or $449 a month by dose; the Wegovy pen is $199 for the first two fills for new patients through December 31, 2026 and $349 after, with the 7.2 mg dose at $399, and the Wegovy pill is $149, $199 or $299 by dose [1]. All in, a cash-paying member on the starting Zepbound dose pays $324 a month for two months and $373 after; on the introductory Wegovy pen price, $224 then $423 [1].
WW's insurance coordinators work with commercial plans only, not Medicare, Medicaid or Kaiser, and the company states the Zepbound KwikPen is not eligible for insurance coverage [1]. Medicare beneficiaries have a separate option, the Medicare GLP-1 Bridge, at $50 a month from July 1, 2026 through December 31, 2027, covering the Zepbound KwikPen, Wegovy pen and pill and Foundayo, with prior authorization required [1].
Third-party aggregators put WW's Trustpilot score at about 3.9 out of 5 across more than 1,660 reviews as of September 2026 [1]. Recurring themes in member feedback include billing that is easier to start than to stop, variable wait times and frustration when a wanted medication is not covered [1].
Why it matters for patients
The drug is the same drug wherever it is prescribed, so a program like Med+ is largely a decision about the fee and the format layered on top of it [1]. Brand Zepbound at the starting dose costs $299 a month through Lilly's self-pay tiers no matter which program routes a patient to it; the difference between programs is the membership fee added on [1]. WW does not sell compounded GLP-1s at all, and compounded versions list for less — a month-one median of $197 for compounded semaglutide and $299 for compounded tirzepatide across 14 providers as of September 3, 2026 — while the FDA had logged 990 adverse-event reports for compounded semaglutide and more than 730 for compounded tirzepatide as of May 31, 2026 [1]. Membership is a recurring charge separate from the medication, so total monthly cost and cancellation terms carry more weight than an introductory rate [1]. How many people have enrolled in Med+, and whether employers or insurers will cover the membership fee itself, has not been reported.
What happens next
WW's Med+ introductory offer ends September 8, 2026 at 11:59 p.m. PDT [1]. The Wegovy introductory cash price of $199 for the first two fills runs for new patients through December 31, 2026 [1]. The Medicare GLP-1 Bridge program is scheduled to run through December 31, 2027 [1]. WW has not disclosed what further changes it plans to the platform.
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.